NewLimit
CA - South SFBiotechnology
Focus: NewLimit is a pre-revenue biotech company pioneering epigenetic reprogramming therapies to reverse cellular aging, with recent $435M Series C funding and focus on rare disease applications.
Profile data last refreshed 12h ago · AI intelligence enriched 3w ago
Open Jobs
17+5 this month
Growing — net +5 jobs in 30d
6 jobs added vs 1 removed. Steady team buildout.
Should You Work at NewLimit?
AI assessmentHigh-risk, high-reward early-stage play suitable only for scientists/operators comfortable with moonshot science and multi-year pre-revenue runway.
Why Work Here
- Backed by high-profile founders (Coinbase CEO) and $435M Series C (Jun 2026), offering significant capital runway and media visibility in the hot longevity/aging space.
- Hiring across 7+ departments including emerging capabilities (Single Cell Technology, Predictive Modeling), signaling transition from discovery to early clinical stage.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for NewLimit
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.